MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Part of GemVax & KAEL Co., Ltd., Gemvax AS is a company headquartered in Porsgrunn, Norway, that develops and manufactures pharmaceuticals. It was founded by Mona Elisabeth M��ller. Gemvax AS was acquired by VaxOnco, Inc. from Pharmexa An on October 30, 2008.\nThe company says this about itself: Based in Seoul, Korea, GemVax Group operates in two main areas: environmental protection and biopharmaceutical drug development. The biopharmaceutical arm, GemVax & KAEL was formed in 1998 and comprises Samsung Pharm, GemVax and FEELingK. It has brought to the market the first-in-class immunotherapeutic drug RIAVAX��inj for pancreatic cancer. Based on telomerase modification, the company's lead candidate GV1001 also has potential other indications in cancer and neurodegenerative diseases.

4Life is a natural supplement distribution company. It employs independent distributors to sell and market the company. All of the 4Life supplements are naturally derived and scientifically proven. These supplements are sure to drive results. Many purposes are suited within the daily intake of 4Life supplements. Different formulas build the immune system, fight diseases, prevent sickness, aid in weight loss, support daily body function, as well there are protein supplements and a whole skincare line. 4Life has a little something for everyone!

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Angioblast Systems, Inc., a biotechnology company, engages in the development and commercialization of therapeutic products for the treatment of cardiovascular diseases. It provides adult stem cells, protein therapeutics, gene silencing, small molecule peptides and antibodies, cytokines and antigen-receptor inhibitors, and DNAzymes, as well as MPC products for heart failure, heart attacks, peripheral artery diseases, and wound ulcers. The company has a strategic alliance with Mesoblast Limited. Angioblast Systems, Inc. was founded in 2001 and is headquartered in New York, New York.

Seattle-based biotechnology company focused on targeting cancer to transform lives through the discovery, development and commercialization of novel therapeutics to fight cancer. Dendreon applies its expertise in antigen identification, engineering and cell processing to produce Active Cellular Immunotherapy (ACI) product candidates designed to stimulate an immune response. ACI holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. In addition to ACI product candidates, the company is also developing an orally-available small molecule targeting TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia.

Genetics Institute is a U.S. based biotechnology research and development company. The company developed drugs such as Neumega and Recombinate used in the prevention of severe reductions in the number of blood clotting cells. The company was founded in 1980 by Thomas Maniatis and Mark Ptashne, and started off by operating out of Ptashne’s home. Genetics Institute was acquired by Wyeth in 1992 and operates as part of Wyeth’s research division.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Stem Cell Medicine is a biotechnology company that develops second generation cell therapy products as stand-alone treatments or in combination with pharmaceuticals, with a focus on neurological indications, including multiple sclerosis, pain and neuromuscular injuries. The company also manages the production, registration and marketing of such products.

Norwood Immunology Pty Ltd. develops and commercializes immunology-related technologies for medical technology. The company was founded in December 2000 and is headquartered in Melbourne, Australia.

Anergen is a brand of hypoallergenic cat and dog food manufactured by Wysong.

DiNonA, Inc. engages in the development of bio-drugs and medical devices. It operates through the Bio Medical and Medical Equipment business divisions. It offers antibody treatments, laser medical devices, and diagnostic reagents. The company was founded on February 11, 1999 and is headquartered in Seoul, South Korea.

Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses. Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.